Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Wegovy (semaglutide) has racked up another indication
Audit Alert Annual RAF Capture Requirement Under CMS-HCC risk adjustment, chronic conditions including obesity must be documented and coded at least once per calendar year to receive credit
Semaglutide is the only GLP-1 monoagonist with completed cardiovascular outcome data in both diabetic and non-diabetic populations
And so the dosages have to be different
Examples include AstraZenecas investment in Eccogene and Roches agreement to buy GLP-1 drug developer Carmot Therapeutics for up to $3.1bn in December 2023
US$ 22.71
US$ 27.03
US$ 20.12
US$ 21.56
US$ 29.86
US$ 21.74
US$ 29.87
US$ 25.69
